← All trials
NCT05346601
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 2, 2022
- Primary completion
- Oct 30, 2022
- Completion date
- Oct 30, 2033
- First posted
- Apr 26, 2022
- Last posted
- Jul 21, 2022
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chipscreen Biosciences, Ltd.Lead sponsor
- Suzhou Medical CollegeOverall official - principal investigator
- H & J CRO International, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.